FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896738977> ?p ?o ?g. }

• W2896738977 endingPage "e292" @default.
• W2896738977 startingPage "e292" @default.
• W2896738977 abstract "SRS is increasingly used as a standard treatment option for breast cancer brain metastases. It is unclear for these patients what are the factors that drive neurologic death. Between 7/2001 and 3/2017, a total of 129 patients with breast cancer brain metastases were treated with upfront SRS alone. Survival was estimated using the Kaplan-Meier method. Cumulative incidence (CI) of distant brain failure (DBF) and neurologic death were estimated using competing risk methodology. Clinicopathologic factors including age, ER/PR status, Her2 status, numbers of brain metastases treated, minimum SRS dose, disease-specific GPA, extracranial disease status and systemic disease burden were evaluated as potential predictors of neurologic death using stepwise multivariate subdistribution hazard modeling. Median follow-up was 9.9 months (IQR, 2.7-21.6). Overall survival at 6, 12 and 24 months for the entire population was 78%, 56%, and 31%. Cumulative incidence of distant brain failure at 6, 12 and 24 months for the entire population was 24%, 41%, and 51%. One-year CI of DBF for ER/PR positive, negative, and unknown patients was 47%, 38%, and 12%, respectively (Gray’s p=0.06). Stratified by Her2 status, 1-year DBF rates were 40%, 45% and 12%, respectively (p=0.07). Median brain metastasis velocity (BMV) was 4.86 (IQR 1.8-11.4). BMV was not associated with ER/PR or Her2 status (p=0.50). Cumulative incidence of neurologic death at 6, 12 and 24 months for the entire population was 9%, 17%, and 19%. Cumulative incidence of non-neurologic death at 6, 12 and 24 months for the entire population was 16%, 31%, and 40%. ER or PR positivity was associated with a trend towards decreased neurologic death (sHR = 0.54, p=0.06). Factors associated with non-neurologic death include age (sHR = 1.02, p=0.03) and extracranial disease status (p=0.02); Her2-positivity was associated with reduced hazard of non-neurologic death (sHR 0.52, p=0.05). Cox proportional hazards analysis of patients who experienced DBF revealed BMV to be highly predictive of both OS (HR = 1.03, p<0.01) and neurologic death (HR = 1.04, p<0.01). ER/PR positivity was associated with a trend towards less neurologic death, while HER2 positivity was associated with a trend towards less non-neurologic death. High BMV was associated with both poor prognosis and high rate of neurologic death. If these data can be validated, they would provide important prognostic biomarkers for cause of death in breast cancer brain metastasis patients." @default.
• W2896738977 created "2018-10-26" @default.
• W2896738977 creator A5002293223 @default.
• W2896738977 creator A5004761876 @default.
• W2896738977 creator A5013288976 @default.
• W2896738977 creator A5013660394 @default.
• W2896738977 creator A5022205130 @default.
• W2896738977 creator A5039382964 @default.
• W2896738977 creator A5042254050 @default.
• W2896738977 creator A5053216668 @default.
• W2896738977 creator A5056625680 @default.
• W2896738977 creator A5059467122 @default.
• W2896738977 creator A5071236953 @default.
• W2896738977 creator A5075426616 @default.
• W2896738977 creator A5076321003 @default.
• W2896738977 creator A5083843932 @default.
• W2896738977 creator A5085848672 @default.
• W2896738977 creator A5091399835 @default.
• W2896738977 date "2018-11-01" @default.
• W2896738977 modified "2023-10-05" @default.
• W2896738977 title "Potential Prognostic Markers for Survival and Neurologic Death in Patients with Breast Cancer Brain Metastases who Receive upfront SRS Alone" @default.
• W2896738977 cites W1513915183 @default.
• W2896738977 cites W1550632220 @default.
• W2896738977 cites W1742681720 @default.
• W2896738977 cites W1974820090 @default.
• W2896738977 cites W1975088650 @default.
• W2896738977 cites W2009776759 @default.
• W2896738977 cites W2015998836 @default.
• W2896738977 cites W2060654645 @default.
• W2896738977 cites W2083128109 @default.
• W2896738977 cites W2103363373 @default.
• W2896738977 cites W2131659761 @default.
• W2896738977 cites W2136568031 @default.
• W2896738977 cites W2169223778 @default.
• W2896738977 cites W2169923878 @default.
• W2896738977 cites W2172075995 @default.
• W2896738977 cites W2185774221 @default.
• W2896738977 cites W2329793926 @default.
• W2896738977 cites W2511092051 @default.
• W2896738977 cites W2582449552 @default.
• W2896738977 cites W2587927846 @default.
• W2896738977 cites W2612391705 @default.
• W2896738977 cites W2746097418 @default.
• W2896738977 cites W2973080678 @default.
• W2896738977 doi "https://doi.org/10.1016/j.ijrobp.2018.07.926" @default.
• W2896738977 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6255726" @default.
• W2896738977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30538888" @default.
• W2896738977 hasPublicationYear "2018" @default.
• W2896738977 type Work @default.
• W2896738977 sameAs 2896738977 @default.
• W2896738977 citedByCount "6" @default.
• W2896738977 countsByYear W28967389772019 @default.
• W2896738977 countsByYear W28967389772020 @default.
• W2896738977 countsByYear W28967389772021 @default.
• W2896738977 countsByYear W28967389772023 @default.
• W2896738977 crossrefType "journal-article" @default.
• W2896738977 hasAuthorship W2896738977A5002293223 @default.
• W2896738977 hasAuthorship W2896738977A5004761876 @default.
• W2896738977 hasAuthorship W2896738977A5013288976 @default.
• W2896738977 hasAuthorship W2896738977A5013660394 @default.
• W2896738977 hasAuthorship W2896738977A5022205130 @default.
• W2896738977 hasAuthorship W2896738977A5039382964 @default.
• W2896738977 hasAuthorship W2896738977A5042254050 @default.
• W2896738977 hasAuthorship W2896738977A5053216668 @default.
• W2896738977 hasAuthorship W2896738977A5056625680 @default.
• W2896738977 hasAuthorship W2896738977A5059467122 @default.
• W2896738977 hasAuthorship W2896738977A5071236953 @default.
• W2896738977 hasAuthorship W2896738977A5075426616 @default.
• W2896738977 hasAuthorship W2896738977A5076321003 @default.
• W2896738977 hasAuthorship W2896738977A5083843932 @default.
• W2896738977 hasAuthorship W2896738977A5085848672 @default.
• W2896738977 hasAuthorship W2896738977A5091399835 @default.
• W2896738977 hasBestOaLocation W28967389772 @default.
• W2896738977 hasConcept C120665830 @default.
• W2896738977 hasConcept C121332964 @default.
• W2896738977 hasConcept C121608353 @default.
• W2896738977 hasConcept C126322002 @default.
• W2896738977 hasConcept C141071460 @default.
• W2896738977 hasConcept C143998085 @default.
• W2896738977 hasConcept C207103383 @default.
• W2896738977 hasConcept C2778164965 @default.
• W2896738977 hasConcept C2779013556 @default.
• W2896738977 hasConcept C2908647359 @default.
• W2896738977 hasConcept C44249647 @default.
• W2896738977 hasConcept C50382708 @default.
• W2896738977 hasConcept C530470458 @default.
• W2896738977 hasConcept C61511704 @default.
• W2896738977 hasConcept C71924100 @default.
• W2896738977 hasConcept C72563966 @default.
• W2896738977 hasConcept C88879693 @default.
• W2896738977 hasConcept C99454951 @default.
• W2896738977 hasConceptScore W2896738977C120665830 @default.
• W2896738977 hasConceptScore W2896738977C121332964 @default.
• W2896738977 hasConceptScore W2896738977C121608353 @default.
• W2896738977 hasConceptScore W2896738977C126322002 @default.
• W2896738977 hasConceptScore W2896738977C141071460 @default.
• W2896738977 hasConceptScore W2896738977C143998085 @default.
• W2896738977 hasConceptScore W2896738977C207103383 @default.

• next